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AbstrACt
Introduction Acute kidney injury (AKI) is a frequent 
complication after cardiac surgery with adverse short- 
term and long- term outcomes. Although prevention of AKI 
(PrevAKI) is strongly recommended, the optimal strategy is 
uncertain. The Kidney Disease: Improving Global Outcomes 
(KDIGO) guideline recommended a bundle of supportive 
measures in high- risk patients. In a single- centre trial, 
we recently demonstrated that the strict implementation 
of the KDIGO bundle significantly reduced the occurrence 
of AKI after cardiac surgery. In this feasibility study, 
we aim to evaluate whether the study protocol can be 
implemented in a multicentre setting in preparation for a 
large multicentre trial.
Methods and analysis We plan to conduct a prospective, 
observational survey followed by a randomised controlled, 
multicentre, multinational clinical trial including 280 
patients undergoing cardiac surgery with cardiopulmonary 
bypass. The purpose of the observational survey is to 
explore the adherence to the KDIGO recommendations in 
routine clinical practice. The second phase is a randomised 
controlled trial. The objective is to investigate whether 
the trial protocol is implementable in a large multicentre, 
multinational setting. The primary endpoint of the 
interventional part is the compliance rate with the protocol. 
Secondary endpoints include the occurrence of any AKI 
and moderate/severe AKI as defined by the KDIGO criteria 
within 72 hours after surgery, renal recovery at day 90, 
use of renal replacement therapy (RRT) and mortality at 
days 30, 60 and 90, the combined endpoint major adverse 
kidney events consisting of persistent renal dysfunction, 
RRT and mortality at day 90 and safety outcomes.
Ethics and dissemination The PrevAKI multicentre 
study has been approved by the leading Research Ethics 
Committee of the University of Münster and the respective 
Research Ethics Committee at each participating site. The 
results will be used to design a large, definitive trial.
trial registration number NCT03244514.
IntroduCtIon
Acute kidney injury (AKI) is a well- recognised 
complication after cardiac surgery.1 
Depending on the definition used, AKI occurs 
in up to 45% of cardiac surgery patients, 
and approximately 1%–2% of patients who 
strengths and limitations of this study
 ► This will be the first multinational trial using a 
biomarker- guided approach to detect high- risk pa-
tients for acute kidney injury (AKI).
 ► The strength of the prevention of AKI (PrevAKI) mul-
ticentre project is the combination of a survey with 
a multicentre- randomised controlled trial to explore 
routine clinical practice and to investigate the feasi-
bility of the study protocol in multiple centres.
 ► The PrevAKI multicentre trial is not powered to eval-
uate the preventive effect of the Kidney Disease: 
Improving Global Outcomes bundles on the occur-
rence of AKI and therefore a definitive future trial will 
be needed.
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require renal replacement therapy (RRT).2–4 The under-
lying mechanisms of cardiac surgery- associated AKI are 
not fully understood, but ischaemia- reperfusion injury, 
inflammation and tubular epithelial cell dysfunction 
often contribute.5
Independent of the underlying aetiology, AKI is asso-
ciated with increased morbidity and mortality, especially 
in patients undergoing cardiac surgery with cardiopul-
monary bypass (CPB).6 7 Although most patients develop 
mild AKI, mortality rates in these patients are five times 
higher compared with patients without AKI.8 Moreover, 
patients who survive an episode of severe AKI are at 
high risk of developing chronic kidney disease (CKD), 
which is associated with a worse long- term outcome 
and a tremendous economic burden for the health-
care system.9 Therefore, prevention of AKI has a high 
priority.10 Despite numerous clinical trials using different 
pharmacological treatments, the optimal strategy to 
prevent AKI is unknown.
The Kidney Disease: Improving Global Outcomes 
(KDIGO) guideline from 2012 includes various recom-
mendations to prevent AKI in high- risk patients, 
including the discontinuation of all nephrotoxic agents 
when possible, optimisation of volume status and haemo-
dynamics, consideration of a functional haemodynamic 
monitoring, close monitoring of serum creatinine and 
urine output, avoidance of hyperglycaemia and consider-
ation of alternatives to radiocontrast agents.11
Investigations have revealed that adherence with treat-
ment bundles is often low in routine clinical practice.12 
In addition, treatment bundles need to be applied before 
the condition of interest actually develops. For AKI, this 
means that the KDIGO recommendations should be 
implemented in high- risk patients before the onset of AKI. 
Novel biomarkers have been shown to identify patients at 
high risk for AKI. Although a variety of biomarkers can 
predict AKI after cardiac surgery,13 point- of- care devices 
to measure biomarkers at the bedside are only for neutro-
phil gelatinase- associated lipocalin (NGAL), and tissue 
inhibitor of metalloproteinases-2 and insulin- like growth 
factor- binding protein7 ([TIMP-2]*[IGFBP7]). NGAL is 
influenced by different comorbidities whereas [TIMP-
2]*[IGFBP7] has a very high specificity and very good 
predictive value. Therefore, we decided to use [TIMP-
2]*[IGFBP7] to identify patients at increased risk for 
AKI.14–16
In a single- centre trial, we previously demonstrated 
that biomarker- guided implementation of the cardio-
vascular (CV) surgery AKI bundle (derived from the 
KDIGO bundle) significantly decreased the occurrence 
of AKI in high- risk patients undergoing cardiac surgery 
(55.1% intervention vs 71.7% control group; p=0.004).17 
In preparation for a definitive adequately powered future 
randomised controlled trial (RCT), we designed the 
prevention of acute kidney injury (PrevAKI) multicentre 
feasibility study to test the protocol in a multicentre 
setting.
objectives and aims
Aim 1 (observational study)
To evaluate adherence with the KDIGO guidelines 
in routine clinical practice, we will test the following 
hypothesis:
 ► Hypothesis I: the CV surgery AKI bundle is not applied 
to all high- risk patients undergoing cardiac surgery.
Aim 2 (interventional trial)
To demonstrate that the implementation of the CV 
surgery AKI bundle in cardiac surgery patients at high 
risk for AKI is feasible in a multicentre trial, we will test 
the following hypothesis:
 ► Hypothesis II: it is possible to implement the CV 
surgery AKI bundle in high- risk patients undergoing 
cardiac surgery in the context of a multicentre study.
MEthods And AnAlysIs
design and setting
This study is a prospective, observational survey followed 
by a randomised- controlled, parallel group multicentre 
trial conducted in 12 centres across Europe including the 
UK (online supplementary eTable S1). The concept of 
the study was approved by all members of the steering 
committee (online supplementary eTable S2). The 
protocol follows Consolidated Standards of Reporting 
Trials and the conduct of the study is in accordance with 
the Declaration of Helsinki (version Fortaleza, 2013). 
The flow chart is summarised in figure 1.
Patient and public involvement
In Germany, Italy, Spain and Belgium, patients and public 
were not involved in the research design of the study. 
In the UK, members of the Kidney Patient Association 
reviewed the protocol and were involved in designing the 
patient information sheets. Study results will be published 
open access. At request, patients or their representatives 
will be informed about the results of the trial.
Participants
In the survey, we will include all adult patients under-
going cardiac surgery with CPB on two consecutive days 
in all participating centres.
In the interventional trial, patients need to meet all 
eligibility criteria to participate in the trial. All four inclu-
sion criteria need to be fulfilled prior to randomisation: 
(1) patients undergoing cardiac surgery with CPB, (2) 
urinary [TIMP-2]*[IGFBP7]≥0.3 at 4 hours after CPB, (3) 
age between 18 and 90 years and (4) written informed 
consent. Patients are excluded if any of the following 
criteria is present: pre- existing AKI (≥stage 1), need for 
cardiac assist devices (extracorporeal membrane oxygen-
ation, left ventricular assist device, right ventricular 
assist device, intra- aortic balloon pump), pregnancy or 
breast feeding, known glomerulonephritis/interstitial 
nephritis/vasculitis, CKD with an estimated glomerular 
filtration rate <20 mL/min/1.73 m2, chronic dialysis 
dependency, prior kidney transplant within the last 12 
months and participation in another interventional trial 
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Figure 1 Trial workflow. Patients will be screened in all participating sites for eligibility on a daily basis. Prior to enrolment, 
it is assured that none of the exclusion criteria are present and informed consent process is performed. Four hours after 
cardiopulmonary bypass (CPB), urine samples for the measurement of tissue inhibitor of metalloproteinases-2 and insulin- like 
growth factor- binding protein 7 [TIMP-2]*[IGFBP7] will be collected. In case [TIMP-2]*[IGFBP7] is ≥0.3, patients are at high risk 
and randomisation can be performed. Patients in the intervention group will receive a functional haemodynamic monitoring 
(according to the routine of each centre) immediately after randomisation and haemodynamic situation will be optimised 
according to a haemodynamic algorithm (figure 2). Laboratory test will be analysed and variables relevant for the assessment 
of renal and haemodynamic situation and safety will be recorded. Follow- up will be performed after 30, 60 and 90 days. ACEi, 
ACE inhibitors; AKI, acute kidney injury; ARBs, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; 
HES, hydroxyethyl starch; KDIGO, Kidney Disease: Improving Global Outcomes; RRT, renal replacement therapy; SCr, serum 
creatinine.
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within the last 3 months. In addition, patients with any 
kind of relationship with the investigator or employed by 
the sponsor/investigator and patients held in an institu-
tion by legal or official order will not be included in the 
trial.
Consent process
For the survey, written informed consent will be obtained 
according to the country- specific requirement of the 
research ethics committee.
For the interventional trial, a member of the research 
team will inform the patient about the nature of the trial, 
its aims, potential benefits as well as possible risks (online 
supplementary material 1). Participants will be asked to 
give written consent to participate in the study prior to 
surgery. The consent form will be countersigned by a 
member of the research team. The original document 
will be stored in a secure place and the patient will receive 
a copy. If the patient is unable to provide written consent, 
a legally authorised representative will be consulted. If an 
authorised representative is not immediately available, 
the research team will follow the agreed recommenda-
tions of their local research ethics committee or country- 
specific institutional review boards.
All data will be kept confidential and will be stored in 
pseudonymised form. The patient has the right to with-
draw from the study at any time without providing a reason 
and without their medical treatment being affected.
observation
In the observational part, all adult patients undergoing 
cardiac surgery in the participating centres will be 
included. Data regarding routine management will be 
collected, especially the adherence with the different 
elements of the KDIGO bundle (online supplementary 
material 2). This includes (1) discontinuation of all neph-
rotoxic agents, (2) optimisation of volume status and 
haemodynamics (target mean arterial pressure (MAP) 
≥65 mm Hg (not fulfilled if MAP is <65 mm Hg and no 
treatment is initiated to achieve this goal), (3) functional 
haemodynamic monitoring (including echocardiog-
raphy, pulse contour cardiac output or pulmonary artery 
catheter), (4) close monitoring of serum creatinine 
every 12 hours and urine output hourly, (5) avoidance 
of hyperglycaemia (blood glucose levels ≤150 mg/dL or 
≤8.3 mmol/L) and (6) avoidance of radiocontrast agents.
randomisation and blinding
In the interventional trial, randomisation will be 
performed centrally using a web- based randomisation 
system provided by the European Society of Intensive 
Care Medicine. Randomisation lists will be stratified by 
centre, and generated using block randomisation with 
randomly varying block sizes. Randomisation assignment 
(in a 1:1 ratio to the two treatment arms) will be given 
only to those patients who fulfil the inclusion criteria and 
have none of the exclusion criteria, and where informed 
consent has been obtained. The treatment protocol will 
be applied immediately after randomisation.
Blinding of the intervention is not possible. Study inter-
vention will be performed by clinical staff involved in 
anaesthesia and perioperative care. Endpoint assessment 
will be performed by a blinded researcher not involved 
in providing anaesthesia and perioperative care. Patients 
will remain blinded to allocation.
treatment
In the survey, there will be no study- related treatment 
procedures. Every patient will be treated according to the 
standards at the individual centre.
In the interventional trial, 4 hours after CPB, urinary 
[TIMP-2]*[IGFBP7] will be measured to identify patients 
at high risk for AKI. Patients with a value ≥0.3 (ng/
mL)2/1000 will be randomised to one of the two treat-
ment arms.
Control group: patients will receive standard of care as 
per centre.
Intervention group: the CV surgery AKI bundle will be 
strictly implemented.
At different time points, blood and urine samples from 
recruited patients will be collected to analyse different 
biomarkers. All other therapies will be directed by the 
patient’s clinical team. All medications will be dose 
adjusted according to renal function in accordance with 
standard dosing guidelines.
CV surgery AKI bundle
The CV surgery AKI bundle includes the following 
measures:
 ► Discontinuation of all nephrotoxic agents if possible.
 ► Haemodynamic monitoring and optimisation 
according to a predefined haemodynamic algorithm 
(figure 2).
 ► Close monitoring of serum creatinine (twice a day), 
fluid balance (twice a day) and urine output (every 
hour as long as the patient has a Foley catheter; if the 
patient does not have a Foley catheter, the urine is 
collected for a certain time period and divided by the 
number of hours to calculate hourly urine volume).
 ► Avoidance of hyperglycaemia (defined as >150 mg/
dL for more than 3 hours) by close monitoring for the 
first 72 hours after surgery.
 ► Consideration of alternatives to radio contrast agents.
 ► Discontinuation of ACE inhibitors and angiotensin II 
receptor blockers for the first 48 hours after surgery.
 ► Avoidance of hydroxyethyl starch, gelatin and 
chloride- rich solutions.
outcomes
In the survey, we will explore whether the different 
elements of the KDIGO bundle are already incorporated 
into routine clinical practice in the different centres. The 
primary endpoint of this observation is the binary indi-
cator whether the CV surgery AKI bundle is completely 
fulfilled at all times or not.
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Figure 2 Haemodynamic algorithm of the intervention group. Patients of the intervention group will receive a functional 
haemodynamic monitoring and an optimisation according to a haemodynamic algorithm consisting of three steps which need 
to be checked every 3 hours: step 1—performance of the passive leg raising test. If the cardiac output (CO) increases by >10%, 
then volume has to be supplemented (crystalloids 500–1000 mL according to the treating intensivist). If CO is ≤10%, step 2—
measurement of the cardiac index (CI). If the CI is <2.5 L/min/m2, then dobutamine or epinephrine (according to the treating 
intensivist) needs to be applied. If CI is >2.5 L/min/m2, then step 3—measurement of mean arterial pressure (MAP). If the MAP is 
<65 mm Hg, then norepinephrine needs to be adjusted. If MAP is >65 mm Hg, then the goal is achieved. This is checked every 
3 hours up to 12 hours after randomisation. PLRT, passive leg raising test.
Secondary outcomes will include
 ► adherence to the different components of the KDIGO 
bundle.
The primary outcome of the interventional trial is the 
compliance rate defined as proportion of patients who 
are treated according to the trial protocol (CV surgery 
AKI bundle fulfilled at all time). Adherence to the trial 
protocol is achieved if all elements of the bundle are 
followed. In addition, we will calculate the adherence 
with the different individual components of the bundle.
Secondary outcomes include:
 ► Occurrence of AKI within the first 72 hours after 
cardiac surgery (AKI as defined by the KDIGO 
criteria).
 ► Moderate and severe AKI within 72 hours (according 
to the KDIGO criteria).
 ► Free days through day 28 of vasoactive medications 
and mechanical ventilation.
 ► Renal recovery (defined as serum creatinine <0.5 mg/
dL higher than baseline) at days 30, 60 and 90.
 ► All- cause mortality at days 30, 60 and 90.
 ► Length of stay in intensive care unit and hospital.
 ► Use of RRT at days 30, 60 and 90.
 ► Major adverse kidney events (MAKE90 consisting 
of mortality, dialysis dependency persistent renal 
dysfunction at day 90).
 ► Determination of different biomarkers (eg, TIMP2, 
IGFBP7, NGAL, kidney injury molecule-1, chitinase, 
hyaluronic acid).
 ► Complications related to the implementation of the 
KDIGO guidelines documented (eg, arrhythmias).
sample size
For the survey, no power analysis is required. The number 
of patients is based on surgical volumes in the two consec-
utive days prior to the interventional trial and is expected 
to be about n=100.
In the interventional trial, 1000 patients will be assessed 
for eligibility, and 280 patients will be enrolled into the 
trial and randomised (based on our previous findings). 
This sample size is determined as follows:
Patients will be randomised in a 1:1 ratio to one of the 
two treatment arms (intervention vs control). Randomisa-
tion serves to estimate the incidence of AKI as a secondary 
outcome to generate preinformation in preparation for 
an upcoming confirmatory trial.
The primary endpoint of the interventional trial is the 
compliance rate, that is, the proportion of patients treated 
according to the trial protocol (intervention group: CV 
surgery AKI bundle fulfilled at all time; control group: 
documented standard of care according to current clin-
ical practice). In order to estimate the compliance rate, 
the two treatment groups will be pooled together. In the 
primary analysis, the compliance rate across all study 
patients will be estimated along with a two- sided 95% CI.
As the compliance rate cannot be quantified in advance, 
we pursue a worst- case approach and assume a compli-
ance rate of 50%. In this case, the CI has maximal width. 
Based on this assumption, with a sample size of n=280 
patients, the calculated 95% CI according to Clopper- 
Pearson (Fleiss 2003) ranges from 44% to 56%. There-
fore, in case of any observed compliance rate apart from 
the worst- case scenario, the 95% CI is never wider than 
56%−44%=12%. This corresponds to an estimation of the 
compliance rate with a precision of ±6%.
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statistical analysis
The study is designed to examine the feasibility of the 
trial protocol in a multicentre setting (as previously 
described).
In the observational study, we will evaluate whether the 
different elements of the KDIGO guidelines are already 
implemented in routine clinical practice. The primary 
endpoint of the observational study is the binary indicator 
whether the CV surgery AKI bundle is completely fulfilled 
at all times or not. Descriptive data analyses will include the 
calculation of means, SD and absolute and relative frequen-
cies. No formal statistical hypothesis will be tested.
In the interventional trial, beyond descriptive analyses, 
inferential statistical analyses will be performed. In the 
primary statistical analysis, the two treatment groups will 
be pooled together and the compliance rate across all 
recruited study patients will be estimated along with a two- 
sided 95% CI according to Clopper- Pearson (Fleiss 2003).
Randomisation serves to estimate the incidence of AKI 
separately in two treatment groups as secondary outcome, 
in order to generate preinformation in preparation for 
an upcoming confirmatory trial. Randomisation will be 
checked by suitable two- sided statistical tests (χ2, or Fish-
er’s exact test for categorical data, Students’ t- test or Mann- 
Whitney U tests for continuous data). If normality of the 
data is not given, non- parametric methods will be used. 
Secondary endpoints will be analysed in the intention 
to treat collective using Fisher’s exact tests or χ2 tests for 
categorical data, and Student’s t- tests or Mann- Whitney U 
tests for continuous data. In a secondary analysis, we will 
investigate whether there is a difference in the incidence 
of AKI as defined by serum creatinine, urine output and 
the composite of the two between the treatment groups. 
Prognostic risk factors for AKI will be identified using a 
multivariable logistic regression analysis, accounting for 
confounding factors. In particular, based on a full model 
with potentially relevant covariates (eg, sex, age, previous 
heart surgery, preoperative creatinine), the final model 
will be established applying a stepwise variable selection 
procedure.
Ethics and dissemination
The PrevAKI- multicentre study has been approved by 
the leading Research Ethics Committee of the Univer-
sity of Münster (2017-291 f- S) and the corresponding 
Research Ethics Committee at each participating site 
(online supplementary eTable S3). Trial oversight will 
be performed by an independent Data Safety and Moni-
toring Board. The task is to oversee the safety of the 
trial subjects and to monitor integrity and validity of the 
conduct of the clinical trial.
The results will be presented at national as well as 
international conferences. The final manuscript will be 
published in a peer- reviewed journal and results will be 
used to design a large multicentre trial with the primary 
objective to investigate whether the implementation of 
the CV surgery AKI bundle reduces the occurrence of 
AKI in high- risk patients undergoing cardiac surgery.
The Standard Protocol Items: Recommendations forIn-
terventional Trials checklist is included in the online 
supplementary material.
dIsCussIon
The PrevAKI- multicentre study is a prospective, observa-
tional survey followed by randomised controlled, multi-
centre and multinational, clinical trial with the primary 
goal to investigate the feasibility of the study protocol in 
a multicentre and multinational setting. In the absence 
of any preventive pharmacological options, the KDIGO 
guidelines recommend a bundle of supportive measures 
in patients at high risk for AKI.11 Whether these recom-
mendations truly reduce the occurrence of AKI remains 
to be confirmed. In the first single- centre randomised 
controlled PrevAKI trial, we could demonstrate that the 
new renal biomarkers [TIMP-2]*[IGFBP7] identified 
patients at high risk for the development of AKI and 
that the CV surgery AKI bundle significantly reduced 
the occurrence of AKI by 15%.17 A further single- centre 
trial demonstrated similar results in patients undergoing 
major abdominal surgeries receiving a bundled interven-
tion.18 However, these were single- centre trials and single- 
centre trials often show positive results. A large RCT is 
needed to confirm these findings. In preparation, it is 
necessary to explore first how many patients are already 
treated according to the KDIGO recommendations and 
second whether the implementation of the CV surgery 
AKI bundle is feasible in a multicentre, multinational 
setting. The results will inform the researchers whether 
changes to the protocol are required before proceeding 
with a large trial to reduce the occurrence of AKI after 
cardiac surgery.
trial status
Recruitment started in November 2017. We estimate to 
complete the study in January 2020.
Author affiliations
1Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, 
Munster, Nordrhein- Westfalen, Germany
2Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
London, UK
3Department of Anesthesiology and Operative Intensive Care, University Hospital 
Marburg, Marburg, UK
4Anesthesiology & Intensive Care Medicine, Philipps- Universitat Marburg 
Fachbereich Medizin, Marburg, Germany
5Department of Cardiothoracic Surgery, Philipps- Universitat Marburg Fachbereich 
Medizin, Marburg, Germany
6Intensive Care and Anesthesia Unit, Scientific Institute San Raffaele, Milano, Italy
7Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona, 
Catalunya, Spain
8Department of Anesthesia, Critical Care and Pain, King's College London, London, 
UK
9Department of Anesthesia and Critical Care, Centro Cardiologico Monzino IRCCS, 
Milano, Lombardia, Italy
10ICU, Universiteit Gent, Gent, Belgium
11Department of Intensive Care, CHU Brugmann, Brussels, Belgium
12Center for Critical Care Nephrology, Department of Critical Care Medicine, 
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
copyright.
 o
n
 April 22, 2020 at Universiteitsbibliotheek G
ent. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034201 on 6 April 2020. Downloaded from 
7Küllmar M, et al. BMJ Open 2020;10:e034201. doi:10.1136/bmjopen-2019-034201
Open access
13Department of Intensive Care Medicine, Royal Surrey County Hospital NHS Trust, 
Guildford, UK
14Department of Cardiac Surgery, Justus Liebig Universität Giessen Fachbereich 
Medizin, Giessen, Hessen, Germany
15Department of Anaesthesiology, University Hospital Münster, Münster, Germany
16Institute of Biostatistics and Clinical Research, Westfälische Wilhelms- Universität 
Münster, Münster, Germany
Acknowledgements The authors would like to thank all the participating centres 
and corresponding staff member involved in this trial.
Contributors MK, CM, RW, SC, NGN, GT, MH, CA, HW, MI, FM, ADP, MGA, SI, VCS, 
GK, SN, CL, WV, PH, PG, RW performed the study and drafted the manuscript. 
MO and EAJH helped designing the trial, performed the study and drafted the 
manuscript. JK, LF and JG helped designing the trial and drafted the manuscript. 
CW helped designing the trial, performed study coordination and drafted the 
manuscript. MM and AZ conceived the study, designed the trial and drafted the 
manuscript. All authors read and approved the final manuscript. MM and AZ share 
last authorship.
Funding The trial is supported by the European Society of Intensive Care Medicine.
disclaimer The content of this paper is solely the responsibility of the authors and 
does not necessarily represent the official views of the funding agency.
Competing interests MM, JK and AZ have received lecture fees from Astute 
Medical, Fresenius and Baxter, unrelated to the current study. JK and AZ have 
received grant support from Astute Medical, unrelated to the current study. MO 
has received lecture fees from Biomerieux, Fresenius Medical and Baxter. CA 
has received lecture fees from Baxter. LF has received research funding from 
Baxter and Ortho Clinical Diagnostics, consultancy fees from Medibeacon/La Jolla 
Pharmaceuticals and honoraria from Biomerieux/Astute.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Alexander Zarbock http:// orcid. org/ 0000- 0002- 2124- 1714
rEFErEnCEs
 1 Nadim MK, Forni LG, Bihorac A, et al. Cardiac and vascular Surgery- 
Associated acute kidney injury: the 20th international consensus 
conference of the ADQI (acute disease quality initiative) group. J Am 
Heart Assoc 2018;7. doi:10.1161/JAHA.118.008834. [Epub ahead of 
print: 01 Jun 2018].
 2 Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal 
risk stratification. Circulation 1997;95:878–84.
 3 Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is 
associated with increased long- term mortality after cardiothoracic 
surgery. Circulation 2009;119:2444–53.
 4 Koyner JL, Bennett MR, Worcester EM, et al. Urinary cystatin C as an 
early biomarker of acute kidney injury following adult cardiothoracic 
surgery. Kidney Int 2008;74:1059–69.
 5 Rosner MH, Okusa MD. Acute kidney injury associated with cardiac 
surgery. Clin J Am Soc Nephrol 2006;1:19–32.
 6 Wijeysundera DN, Karkouti K, Dupuis J- Y, et al. Derivation and 
validation of a simplified predictive index for renal replacement 
therapy after cardiac surgery. JAMA 2007;297:1801–9.
 7 Ostermann ME, Taube D, Morgan CJ, et al. Acute renal failure 
following cardiopulmonary bypass: a changing picture. Intensive 
Care Med 2000;26:565–71.
 8 Kellum JA, Bellomo R, Ronco C. Kidney attack. JAMA 
2012;307:2265–6.
 9 Basile DP, Bonventre JV, Mehta R, et al. Progression after AKI: 
understanding maladaptive repair processes to predict and identify 
therapeutic treatments. J Am Soc Nephrol 2016;27:687–97.
 10 Kellum JA, Angus DC. Patients are dying of acute renal failure. Crit 
Care Med 2002;30:2156–7.
 11 Kellum J ALN, Aspelin P, Barsoum RS, et al. KDIGO clinical 
practice guideline for Acte kidney injury 2012. Kidney Int Suppl 
2012;2:1–138.
 12 Leone M, Ragonnet B, Alonso S, et al. Variable compliance with 
clinical practice guidelines identified in a 1- day audit at 66 French 
adult intensive care units. Crit Care Med 2012;40:3189–95.
 13 Parikh CR, Coca SG, Thiessen- Philbrook H, et al. Postoperative 
biomarkers predict acute kidney injury and poor outcomes after adult 
cardiac surgery. J Am Soc Nephrol 2011;22:1748–57.
 14 Kashani K, Al- Khafaji A, Ardiles T, et al. Discovery and validation of 
cell cycle arrest biomarkers in human acute kidney injury. Crit Care 
2013;17:R25.
 15 Meersch M, Schmidt C, Van Aken H, et al. Urinary TIMP-2 and 
IGFBP7 as early biomarkers of acute kidney injury and renal recovery 
following cardiac surgery. PLoS One 2014;9:e93460.
 16 Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for 
perioperative care in cardiac surgery: enhanced recovery after 
surgery Society recommendations. JAMA Surg 2019. doi:10.1001/
jamasurg.2019.1153. [Epub ahead of print: 04 May 2019].
 17 Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac 
surgery- associated AKI by implementing the KDIGO guidelines in 
high risk patients identified by biomarkers: the PrevAKI randomized 
controlled trial. Intensive Care Med 2017;43:1551–61.
 18 Göcze I, Jauch D, Götz M, et al. Biomarker- Guided intervention 
to prevent acute kidney injury after major surgery: the prospective 
randomized BigpAK study. Ann Surg 2018;267:1013–20.
copyright.
 o
n
 April 22, 2020 at Universiteitsbibliotheek G
ent. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034201 on 6 April 2020. Downloaded from 
